<DOC>
	<DOC>NCT02866149</DOC>
	<brief_summary>Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.</brief_summary>
	<brief_title>Analysis of Circulating Tumor Markers in the Blood (ALCINA)</brief_title>
	<detailed_description>Exploratory multi-cohort study including different types of cancer (different organs and/or different histological types). Each kind of blood-borne biological markers analyses corresponds to a cohort.</detailed_description>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>1. Patient with any tumoral disease (proven or suspected), of any type and stage 2. More than18 years old 3. Signed informed consent form Additional inclusion criteria if a tumor sample is needed: 4. Tumor considered as accessible by biopsy 5. Normal blood coagulation tests on the last blood analysis Noninclusion Criteria: 1. Patient in detention or protected by the law 2. Patient who cannot comply with the study follow up for geographical, social or psychological reasons Additional noninclusion criteria if a tumor sample is needed: 3. Anticoagulant or antiaggregant that cannot be interrupted for the biopsy 4. centralnervous system metastases only (unless a diagnostic or curative surgery is planned before the inclusion in the study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>circulating tumor biomarkers</keyword>
	<keyword>circulating tumor DNA</keyword>
	<keyword>Circulating tumor Cell (CTC)</keyword>
</DOC>